Drug profile · INN
clofarabine
EVOLTRA
clofarabine (EVOLTRA) is a dna polymerase (alpha/delta/epsilon) inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — clofarabine
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
clofarabine (EVOLTRA) is a dna polymerase (alpha/delta/epsilon) inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA polymerase (alpha/delta/epsilon) inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is clofarabine?
clofarabine (EVOLTRA) is a dna polymerase (alpha/delta/epsilon) inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for clofarabine?
EVOLTRA is a marketed brand name for clofarabine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of clofarabine?
clofarabine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.